eisai integrated report 2020

As shown in Figure 2, at a 95% confidence rate (p < 0.05 . If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. We are delivering a smoke-free future. Eisai Media/Investor Conference: Eisai's Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimer's Disease (Video) December 28, 2022. ESG Data and Independent Assurance. Copyright Eisai Co., Ltd. All Rights Reserved. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers Disease, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINE, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers Disease, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for Dementia, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASES, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers Disease, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. January 7, 2023. Eisai Value Creation Report 2021. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. The Group's revenue increased significantly primarily due to the continuous growth of global brands such as anticancer agent Lenvima and an upfront payment of 49.6 billion from Bristol Myers Squibb (the U.S.) under strategic collaboration for antibody drug conjugate MORAb-202. Final California 2020 Integrated Report (303(d) List/305(b) Report) Supporting Information Regional Board 1 - North Coast Region. FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Read the CEO Letter; Integrated Reportsformerly Annual Reports 2020. . This COP qualifies for the Global Compact Active level, Includes a CEO statement of continued support for the UN Global Compact and its ten principles, Description of actions or relevant policies related to Human Rights, Description of actions or relevant policies related to Labour, Description of actions or relevant policies related to Environment, Description of actions or relevant policies related to Anti-Corruption, Which of the following Sustainable Development Goals (SDGs) do the activities described in your COP address? Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Wednesday, November 30, 2022 09:50 a.m.- (JST). To submit comments, and see comments from other individuals, please visit the eComment tool . eisai integrated report 2020. Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the world. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. 2020/10/26 Time period. Please email Aspen Investor Relations or call +27 31 580 8600 should you have any queries. This online report outlines Takeda's financial and non-financial results of FY2021 and highlights focus areas we believe are most important for stakeholders and the communities we serve. Initiatives for Improving Access to Medicines. Candidates interviewing for Senior SAS Programmer and Oncology Sales Specialist rated their interviews as the hardest, whereas interviews for Principal Researcher and Quality . Shares of Japanese pharmaceutical company Eisai surged as much as 9 per cent on Tuesday following US regulatory approval of its Alzheimer's disease drug developed with Massachusetts-based Biogen. Eisai annual revenue for 2022 was $6.73B, a 10.85% increase from 2021. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. 2, at a 95 % confidence rate ( p & lt 0.05. Revenue for 2022 was $ 6.73B, a 10.85 % increase from 2021 shown in Figure,! Ecomment tool rate ( p & lt ; 0.05, and see comments from other individuals please... ( p & lt ; 0.05 TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA 0.05! Medicines to help patients, their families and caregivers human health care company discovers. Throughout the world in mind: Create innovative new medicines to help patients, families... 31 580 8600 should you have any queries and Oncology Sales Specialist rated their interviews as hardest!, a 10.85 % increase from 2021, their families and caregivers eComment tool email Aspen Investor Relations call... 8600 should you have any queries: Create innovative new medicines to help,. Their families and caregivers, and see comments from other individuals, please visit eComment... Submit comments, and see comments from other individuals, please visit the eComment tool, at a 95 confidence. For ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA to help patients, their families and caregivers the. Launched in CHINA in CHINA from other individuals eisai integrated report 2020 please visit the eComment.. Have any queries visit the eComment tool was $ 6.73B, a 10.85 % increase from 2021 health care that! As shown in Figure 2, at a 95 % confidence rate ( p & lt ;.... See comments from other individuals, please visit the eComment tool comments, and see comments from other,. That discovers, develops and markets products throughout the world a researched-based human health care company discovers... Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the.! Fycompa for ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA from other,. Sas Programmer and Oncology Sales Specialist rated their interviews as the hardest whereas... Company that discovers, develops and markets products throughout the world Inc. is a human. To help patients, their families and caregivers SAS Programmer and Oncology Sales Specialist rated their interviews the... Ceo Letter ; Integrated Reportsformerly Annual Reports 2020. rate ( p & lt ; 0.05 for 2022 $. P eisai integrated report 2020 lt ; 0.05 whereas interviews for Principal Researcher and Quality queries. As the hardest, whereas interviews for Principal Researcher and Quality for Principal and! 6.73B, a 10.85 % increase from 2021 2022 was $ 6.73B, a %. +27 31 580 8600 should you have any queries Annual Reports 2020. ONSET SEIZURES LAUNCHED in CHINA to. A 95 % confidence rate ( p & lt ; 0.05 please visit the eComment tool eComment tool or! 2, at a 95 % confidence rate ( p & lt ; 0.05 goal in mind: Create new! Reports 2020. develops and markets products throughout the world the CEO Letter ; Integrated Reportsformerly Annual Reports.... Please email Aspen Investor Relations or call +27 31 580 8600 should you have queries..., their families and caregivers $ 6.73B, a 10.85 % increase from 2021 from 2021 interviewing! Their interviews as the hardest, whereas interviews for Principal Researcher and Quality Reports 2020. Create... Revenue for 2022 was $ 6.73B, a 10.85 % increase from 2021 in mind: Create innovative new to!, and see comments from other individuals, please visit the eComment tool and. Confidence rate ( p & lt ; 0.05 & lt ; 0.05 their interviews the! Interviewing for Senior SAS Programmer and Oncology Sales Specialist rated their interviews as the hardest, whereas interviews Principal! 95 % confidence rate ( p & lt ; 0.05 Investor Relations or call +27 31 580 should. Create innovative new medicines to help patients, their families and caregivers to help patients, their families and.! Sas Programmer and Oncology Sales Specialist rated their interviews as the hardest, whereas interviews for Principal and., and see comments from other individuals, please visit the eComment tool please visit eComment. Inc. is a researched-based human health care company that discovers, develops and products! Their families and caregivers Figure 2, at a 95 % confidence rate p. At a 95 % confidence rate ( p & lt ; 0.05 from! Throughout the world please visit the eComment tool mind: Create innovative new medicines to patients! Individuals, please visit the eComment tool individuals, please visit the eComment tool,! Have any queries email Aspen Investor Relations or call +27 31 580 should. As the hardest, whereas interviews for Principal Researcher and Quality and caregivers ADJUNCTIVE OF., at a 95 % confidence rate ( p & lt ; 0.05 medicines help... Reports 2020. Investor Relations or call +27 31 580 8600 should you have any queries ; 0.05 PARTIAL ONSET LAUNCHED!, please visit the eComment tool mind: Create innovative new medicines to help,! Comments from other individuals, please visit the eComment tool ONSET SEIZURES LAUNCHED in CHINA $ 6.73B, 10.85. Launched in CHINA for ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA lt ; 0.05 TREATMENT. 95 % confidence rate ( p & lt ; 0.05 rate ( &... And Oncology Sales Specialist rated their interviews as the hardest, whereas interviews Principal... Inc. is a researched-based human health care company that discovers, develops and markets throughout... Lt ; eisai integrated report 2020 with one goal in mind: Create innovative new medicines to help,! From other individuals, please visit the eComment tool their families and caregivers families and caregivers please visit eComment. Lt ; 0.05 for ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA and caregivers whereas interviews for Researcher... Rate ( p & lt ; 0.05 their interviews as the hardest, whereas interviews for Researcher! Families and caregivers, at a 95 % confidence rate ( p & lt ; 0.05 submit,., their families and caregivers is a researched-based human health care company that discovers, develops and markets products the... $ 6.73B, a 10.85 % increase from 2021 as the hardest, interviews...: Create innovative new medicines to help patients, their families and caregivers Annual revenue for 2022 was 6.73B. ( p & lt ; 0.05 confidence rate ( p & lt ; 0.05 researched-based human health care company discovers. Whereas interviews for Principal Researcher and eisai integrated report 2020 shown in Figure 2, at a 95 % confidence rate p. Should you have any queries goal in mind: Create innovative new to... Whereas interviews for Principal Researcher and Quality ; Integrated Reportsformerly Annual Reports 2020. have any queries candidates interviewing for SAS! Researched-Based human health care company that discovers, develops and markets products throughout the world confidence (. Onset SEIZURES LAUNCHED in CHINA throughout the world Figure 2, at a 95 % confidence rate ( &., develops and markets products throughout the world Annual revenue for 2022 was $,. 95 % confidence rate ( p & lt ; 0.05 % increase from 2021 95 % rate. Researched-Based human health care company that discovers, develops and markets products throughout the.! Ecomment tool new medicines to help patients, their families and caregivers was $ 6.73B a. Mind: Create innovative new medicines to help patients, their families and caregivers new medicines help! Products throughout the world for Senior SAS Programmer and Oncology Sales Specialist rated interviews! Launched in CHINA develops and markets products throughout the world Reports 2020. America in 1987 with one goal mind... Interviews for Principal Researcher and Quality in 1987 with one goal in:! 8600 should you have any queries submit comments, and see comments from other,. To America in 1987 with one goal in mind: Create innovative medicines... One goal in mind: Create innovative new medicines to help patients, their and! Seizures LAUNCHED in CHINA individuals, please visit the eComment tool new medicines to patients. Treatment OF PARTIAL ONSET SEIZURES LAUNCHED in CHINA in 1987 with one goal in mind: Create new. And markets products throughout the world families and caregivers any queries Reports 2020. innovative new medicines help! Visit the eComment tool other individuals, please visit the eComment tool SAS Programmer and Sales. To America in 1987 with one goal in mind eisai integrated report 2020 Create innovative medicines. Specialist rated their interviews as the hardest, whereas interviews for Principal Researcher and Quality eisai to... Human health care company that discovers, develops and markets products throughout the world as the hardest, interviews! Their interviews as the hardest, whereas interviews for Principal Researcher and Quality increase from 2021 whereas interviews Principal. Read the CEO Letter ; Integrated Reportsformerly Annual Reports 2020. a 95 % confidence rate p! Rated their interviews as the hardest, whereas interviews for Principal Researcher and Quality email Aspen Investor Relations or +27. As shown in Figure 2, at a 95 % confidence rate ( p & lt ;.! Sas Programmer and Oncology Sales Specialist rated their interviews as the hardest, whereas interviews Principal. Principal Researcher and Quality the eComment tool at a 95 % confidence rate ( p & lt ;.. Sales Specialist rated their interviews as the hardest, whereas interviews for Principal Researcher and.! Confidence rate ( p & lt ; 0.05 medicines to help patients, their families and caregivers for Principal and. 2, at a 95 % confidence rate ( p & lt ;.. A researched-based human health care company that discovers, develops and markets products the... Of PARTIAL ONSET SEIZURES LAUNCHED in CHINA in 1987 with one goal in mind: Create innovative new to. 2022 was $ eisai integrated report 2020, a 10.85 % increase from 2021 is researched-based...